{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:21Z","timestamp":1791304341737,"version":"4.3.1"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Antibodies that target citrullinated protein\/peptide (ACPA) and homocitrullinated\/carbamylated protein\/peptide (AHCPA) are associated with rheumatoid arthritis (RA). The relationship between ACPA and AHCPA remains unclear. We examined the expression and cross-reactivity of these antibodies using citrulline- and homocitrulline-containing synthetic peptides, CitJED and HomoCitJED, respectively, which have equal numbers of citrulline or homocitrulline residues on the same peptide backbone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Serum from healthy subjects (n = 51) and patients with RA (n = 137), systemic lupus erythematosus (SLE; n = 37), and psoriatic arthritis (PsA; n = 37) were screened for IgG anti-CitJED and anti-HomoCitJED antibodies by ELISA. Cross-reactivity of these antibodies was examined by inhibition with various concentrations of CitJED and HomoCitJED.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Out of 137 patients with RA, antibodies to CitJED and HomoCitJED were detected in 69 (50%) and 78 (57%), respectively. Anti-CitJED and HomoCitJED antibodies were 77% concordant and their levels were strongly correlated [Spearman correlation coefficient (r<jats:sub>s<\/jats:sub>) = 0.6676]. Sera from 25\/27 patients (93%) with RA were inhibited by both CitJED and HomoCitJED with equal or higher affinity for the cognate (homologous) peptide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Antibodies to CitJED and HomoCitJED frequently occurred in RA, but were not found in SLE or PsA, suggesting that these antibodies are specific to RA. Cross-reactivity between anti-HomoCitJED and anti-CitJED antibodies suggests that ACPA and AHCPA are derived from the same B cell population and both may contribute to the pathogenesis of RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.170446","type":"journal-article","created":{"date-parts":[[2017,12,2]],"date-time":"2017-12-02T01:11:15Z","timestamp":1512177075000},"page":"302-309","source":"Crossref","is-referenced-by-count":19,"title":["Relatedness of Antibodies to Peptides Containing Homocitrulline or Citrulline in Patients with Rheumatoid Arthritis"],"prefix":"10.3899","volume":"45","author":[{"given":"Patrick","family":"Lac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Racap\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"key":"2018112909375688000_45.3.302.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1316"},{"key":"2018112909375688000_45.3.302.2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3"},{"key":"2018112909375688000_45.3.302.3","doi-asserted-by":"publisher","DOI":"10.1186\/ar93"},{"key":"2018112909375688000_45.3.302.4","first-page":"2115","article-title":"Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis","volume":"33","author":"Hill","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909375688000_45.3.302.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130742"},{"key":"2018112909375688000_45.3.302.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204154"},{"key":"2018112909375688000_45.3.302.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.37830"},{"key":"2018112909375688000_45.3.302.8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114465108"},{"key":"2018112909375688000_45.3.302.9","unstructured":"Bell DA Elhayek S Cairns E Barra L . Anti-homocitrullinated protein antibody isotype usage in rheumatoid arthritis and their unaffected first-degree relatives. Clin Exp Rheumatol 2017 Jun 5 (E-pub ahead of print)."},{"key":"2018112909375688000_45.3.302.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018"},{"key":"2018112909375688000_45.3.302.11","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.051391"},{"key":"2018112909375688000_45.3.302.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016808"},{"key":"2018112909375688000_45.3.302.13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051951"},{"key":"2018112909375688000_45.3.302.14","first-page":"S433","article-title":"The mechanisms underlying arthritogenicity of human anticitrulline antibodies [abstract]","volume":"58","author":"Brintnell","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2018112909375688000_45.3.302.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.27644"},{"key":"2018112909375688000_45.3.302.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201559"},{"key":"2018112909375688000_45.3.302.17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-014-0515-z","article-title":"Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides","volume":"17","author":"Turunen","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2018112909375688000_45.3.302.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206785"},{"key":"2018112909375688000_45.3.302.19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-016-1001-6","article-title":"Antibodies to carbamylated \u03b1-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies","volume":"18","author":"Reed","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2018112909375688000_45.3.302.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2018112909375688000_45.3.302.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400928"},{"key":"2018112909375688000_45.3.302.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2018112909375688000_45.3.302.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.27533"},{"key":"2018112909375688000_45.3.302.24","unstructured":"Hill JA Cairns E Bell DA , inventors. Peptides associated with MHC class II molecules involved in autoimmune diseases. United States full patent application (US10\/548258) filed 2004 Mar 5; published 2007 Dec 20. Canadian full patent application (CA2518187) filed 2005 Sept 20. Patent Treaty Cooperation Application (WO 04\/078098) filed 2004 Mar 5 to secure worldwide protection. Europe (EP1603937) published 2005 Dec 14. Japan (JP2007524583) published 2007 Aug 30. Australia (AU4216925) issued 2010."},{"key":"2018112909375688000_45.3.302.25","doi-asserted-by":"crossref","unstructured":"Jiang X Trouw LA van Wesemael TJ Shi J Bengtsson C K\u00e4llberg H Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis 2014:1761\u20138.","DOI":"10.1136\/annrheumdis-2013-205109"},{"key":"2018112909375688000_45.3.302.26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13075-016-1173-0","article-title":"Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases","volume":"18","author":"Pecani","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2018112909375688000_45.3.302.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161432"},{"key":"2018112909375688000_45.3.302.28","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0860-6"},{"key":"2018112909375688000_45.3.302.29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13075-016-1192-x","article-title":"Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts","volume":"18","author":"Ziegelasch","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2018112909375688000_45.3.302.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207751"},{"key":"2018112909375688000_45.3.302.31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000075"},{"key":"2018112909375688000_45.3.302.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124537"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:25:31Z","timestamp":1543519531000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.3899\/jrheum.170446"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170446","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}